With patents on several blockbuster therapeutic proteins soon to expire and several companies pondering whether to manufacture their own versions of these medicines, can a commercially viable business be based on biogenerics?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Australia and New Zealand Health Policy Open Access 01 June 2007
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Dove, A. Betting on biogenerics. Nat Biotechnol 19, 117–120 (2001). https://doi.org/10.1038/84365
Issue Date:
DOI: https://doi.org/10.1038/84365
This article is cited by
-
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Australia and New Zealand Health Policy (2007)
-
Through the looking glass: the protein science of biosimilars
Clinical and Experimental Nephrology (2007)
-
Biosimilars: initial excitement gives way to reality
Nature Reviews Drug Discovery (2006)
-
Teva to acquire Chinese biogenerics manufacturer
Nature Biotechnology (2005)
-
Walking the drug regulatory tightrope
Nature Biotechnology (2003)